SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

Share Price is delayed by 15 minutes
Get Live Data
6,785.00    90.00 (1.34%)
Bid:
6,780.00
Ask:
6,790.00
Spread: 10.00 (0.147%)
Market Cap: £5.01b
SPX Live PriceLast checked at - London Stock Exchange

Intraday Spirax-Sarco Share Chart

Interim Management Statement

9 May 2013 07:00

RNS Number : 2857E
Spirax-Sarco Engineering PLC
09 May 2013
Β 

ο»Ώ

Β 

Β 

News Release

Β 

Thursday 9th May 2013

INTERIM MANAGEMENT STATEMENT

Β 

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam and in peristaltic pumping, issues the following Interim Management Statement in respect of the period from 1st January 2013, ahead of its Annual General Meeting ("AGM") today at 2.00pm.

Β 

Trading

Global economic conditions remain broadly unchanged since we reported our 2012 results in early March and trading conditions in most of our markets have been similar to the second half of last year: we continue to see reasonably good base business but restrained customer expenditure for more costly plant improvement and energy saving projects.

Β 

2013 has started in line with our expectations and ahead of last year. For the four months ended 30th April 2013, sales increased by 6%, including a gain of 2% from favourable currency movements as sterling weakened. We achieved growth in all segments, led by good organic sales growth in Asia Pacific followed by Watson-Marlow. We saw modest organic sales growth in Europe, Middle East and Africa ("EMEA"), which was encouraging given the difficult economic background. In the Americas, strong progress in Latin America offset a decline in the US and Canada, where the softness towards the end of 2012 has continued into 2013.

Β 

At constant currency, operating profit and margin were comfortably ahead of the comparable period in 2012 reflecting the contribution from higher sales and, importantly, the further cost savings from the restructuring in Europe, net of increased costs from continued investments in market development. The performance in EMEA was markedly ahead, aided also by favourable currency movements.

Β 

Financial position

Our balance sheet remains very strong and the Group's net cash balance increased from Β£52 million at 31st December 2012 to Β£76 million at 30th April 2013, including Β£5 million due to more favourable exchange rates. If approved at the AGM, the final dividend of 37p per share in respect of 2012, totalling Β£29 million, will be paid on 17th May 2013 and the special dividend of 100p per share, totalling Β£78 million, will be paid on 3rd July 2013. There has been no material change in the financial position of the Group during the period and the principal risks and uncertainties remain as set out on pages 55 to 59 of the 2012 Annual Report.

Β 

Outlook

As noted in previous statements, our markets tend to broadly mirror overall economic activity and industrial production. We anticipate that low rates of industrial production growth will persist this year in most of our mature markets and that conditions in Europe will remain weak but offset by generally higher rates of industrial output in our emerging markets. Our focus is on generating our own growth through our strategic priorities of expanding our presence in emerging markets and driving benefits from the increased investment in R&D in recent years, as well as delivering the full-year cost savings of the European restructuring.

Β 

Our business is seasonally biased to the second half and we are anticipating a more normal first half/second half profile this year. Given the Group's robust business model and fundamental strengths, the Board remains confident that the Group will make further progress in 2013.

Β 

Spirax Sarco will publish its interim results on 8th August 2013.

Β 

Β 

Enquiries:

Mark E Vernon, Chief Executive

David Meredith, Director Finance

Tel: 01242 535234

Β 

Β 

Β 

Β 

About Spirax Sarco

Spirax-Sarco Engineering plc is the world leader in both steam system management and peristaltic pumping. The Company provides a broad range of fluid control products, engineered packages, site services and systems expertise for its diverse range of over 100,000 industrial and institutional customers. The Company helps its customers to optimise production capacity, reduce energy costs and emissions, improve product quality and enhance the safety of their operations. Spirax Sarco is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs approximately 4,700 people, of whom around 1,300 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX). Further information can be found at www.spiraxsarcoengineering.comΒ 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSBLGDUBGGBGXI
Date   Source Headline
8th Jun 20261:24 pmRNSDirector/PDMR Shareholding
1st Jun 202610:28 amRNSChange in Major Shareholding
29th May 20262:24 pmRNSUpdate on Directorships held by Company Directors
27th May 20263:30 pmRNSDirector/PDMR Shareholding
26th May 20265:24 pmRNSDirector/PDMR Shareholding
19th May 20269:16 amRNSChange in Major Shareholding
14th May 20262:47 pmRNSExternal Directorships held by Company Directors
14th May 202610:39 amRNSDirector/PDMR Shareholding
13th May 20264:12 pmRNSResult of AGM
13th May 20267:00 amRNSTrading Update
8th May 20263:42 pmRNSChange in Major Shareholding
7th May 20269:03 amRNSDirector/PDMR Shareholding
8th Apr 20262:22 pmRNSDirector/PDMR Shareholding
8th Apr 20269:30 amRNSAnnual Report and Accounts 2025 and Notice of AGM
18th Mar 20264:53 pmRNSDirector/PDMR Shareholding
11th Mar 20261:53 pmRNSTotal Voting Rights
10th Mar 20265:01 pmRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNS2025 Full Year Results
10th Mar 20267:00 amRNS2025 Full Year Results
9th Mar 20263:35 pmRNSDirector/PDMR Shareholding
9th Mar 20263:35 pmRNSDirector/PDMR Shareholding
10th Feb 20269:30 amRNSChange in Director Details
6th Feb 20263:47 pmRNSDirector/PDMR Shareholding
2nd Feb 20261:50 pmRNSChange in Director Details
30th Jan 20262:19 pmRNSHolding(s) in Company
6th Jan 20263:10 pmRNSDirector/PDMR Shareholding
18th Dec 20252:12 pmRNSCorrection: Block Listing Application
18th Dec 20252:12 pmRNSCorrection: Block Listing Application
18th Dec 202510:34 amRNSBlocklisting Application
9th Dec 20252:35 pmRNSDirector/PDMR Shareholding
18th Nov 20259:40 amRNSDirector/PDMR Shareholding
13th Nov 20257:00 amRNSTrading Update
7th Nov 20251:56 pmRNSDirector/PDMR Shareholding
5th Nov 20258:39 amRNSHolding(s) in Company
22nd Oct 20257:00 amRNSBoard Appointment
7th Oct 20255:08 pmRNSDirector/PDMR Shareholding
9th Sep 20257:00 amRNSDirector/PDMR Shareholding
1st Sep 20259:35 amRNSHolding(s) in Company
12th Aug 20257:00 amRNSBoard Committee Membership Update
12th Aug 20257:00 amRNS2025 Half Year Results
7th Aug 20257:00 amRNSDirector/PDMR Shareholding
24th Jul 20254:58 pmRNSDirector/PDMR Shareholding
9th Jul 20254:26 pmRNSDirector/PDMR Shareholding
13th Jun 20253:36 pmRNSDirector/PDMR Shareholding
14th May 20254:48 pmRNSResult of AGM
14th May 20257:00 amRNSTrading Update
8th May 202511:03 amRNSDirector/PDMR Shareholding
23rd Apr 20255:13 pmRNSChange in Director Details
22nd Apr 20253:52 pmRNSDirector/PDMR Shareholding
11th Apr 20255:04 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.